Pharma-bio Serv, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OQB
Pharma-Bio Serv announced improved revenues and net income for the quarter ended April 30, 2026, driven by strategic market focus and cost management.
OQB
Pharma-Bio Serv, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of Irving Wiesen and the ratification of its independent auditors.
OQB
Pharma-Bio Serv, Inc. announced a modest profit of $32,860 for the quarter ended January 31, 2026, despite a $0.2 million decrease in revenues to $2.3 million.
OQB
Pharma-Bio Serv announced full-year 2025 results, reporting a revenue decrease but an improved net loss, alongside a special dividend declaration.
OQB
Pharma-Bio Serv, Inc. announced revenues of $2.0 million and a net loss of $0.2 million for the three months ended July 31, 2025, alongside strategic cost streamlining efforts.
OQB
Pharma-Bio Serv, Inc. announced a significant return to profitability for the quarter and six months ended April 30, 2025, driven by strategic focus on high-margin projects.
OQB
Pharma-Bio Serv, Inc. held its 2025 Annual Meeting of Stockholders on May 15, 2025, where key proposals were voted on, including the election of a director and the ratification of the company's independent auditor.
OQB
Pharma-Bio Serv announces a slight revenue increase and nears breakeven for the quarter ended January 31, 2025, with international projects driving growth.
OQB
8-K: Pharma-Bio Serv Reports Lower Revenues and Net Loss for Fiscal Year 2024, Announces Special Dividend
Pharma-Bio Serv announced a decrease in revenue and a net loss for the year ended October 31, 2024, but declared a special dividend of $0.075 per share.
OQB
Pharma-Bio Serv's Board of Directors has approved a special dividend of $0.075 per share for shareholders.
OQB
Pharma-Bio Serv announced a decrease in revenue and a net loss for the three and nine months ended July 31, 2024, compared to the same periods last year.
OQB
Pharma-Bio Serv announced a decrease in revenue and a net loss for the quarter ended April 30, 2024, compared to the same period last year.
OQB
Pharma-Bio Serv's stockholders approved an extension to the company's 2014 Long-Term Incentive Plan and elected two Class II directors at the 2024 Annual Meeting.
OQB
Pharma-Bio Serv announced a revenue decrease of approximately $1.9 million and a net loss of approximately $270,700 for the quarter ended January 31, 2024, compared to the same period last year.
OQB
Pharma-Bio Serv announced a decrease in revenue but an increase in net income for the year ended October 31, 2023, along with a special dividend for shareholders.